The pivotal trial of the MiniMed 670G HCL system showed that the sensor allowed for the safe delivery of basal insulin, as per the HCL algorithm, in 124 subjects for 3 months, during which time there was no severe hypoglycemia or DKA in over 12,000 days of patient use.19 During a 6-day/5-night hotel stay conducted during the pivotal trial, SG values were compared with venous samples using the i-STAT® (Abbott Laboratories, Abbott Park, IL) as reference, during a 24-h period. This evidence concerns the gene INS and Hypoglycemia.